Top Medical News Today
Charles S. Fuchs, MD, MPH, has been appointed the new director and physician-in-chief of Smilow Cancer Hospital at Yale Cancer Center (YCC) in New Haven, Connecticut.
In patients with metastatic colorectal cancer (mCRC), the correlation between tumor location and improved survival varies based on stage of disease, according to a study.
An expert discusses the potential role for immunotherapy in frontline head and neck cancer, as well as the possible benefit of using it in combination with standard treatments, including radiation and chemotherapy.
Pegylated liposomal irinotecan (Onivyde) in combination with fluorouracil (5-FU) and leucovorin has been approved by the European Commission (EC) for patients with metastatic pancreatic adenocarcinoma.
James P. Allison, PhD, was recently presented with the Association of American Cancer Institutes (AACI) Distinguished Scientist Award in recognition of his extraordinary scientific accomplishments and contributions to cancer research.
View More >
In a recent study, single-agent olaparib (Lynparza) significantly improved progression-free survival (PFS) compared with placebo in the maintenance setting for patients with advanced BRAF-positive ovarian cancer.
Novel Treatment Strategies Emerging for CLL
Jennifer Brown, MD, PhD, director of the CLL Center at the Dana-Farber Cancer Institute and associate professor at Harvard Medical School, discusses the status of targeted therapy agents for the treatment of patients with CLL
Wierda Discusses Current Questions in Frontline CLL Treatment
William G. Wierda, MD, PhD, discusses which groups of CLL patients may benefit from ibrutinib versus chemoimmunotherapy and clinical trials that may provide further clarification.
Blinatumomab Receives FDA Approval for Acute Lymphoblastic Leukemia
Blinatumomab (Blincyto) has received accelerated approval from the FDA for the treatment of pediatric and adolescent patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
NDA for Neratinib in HER2-Positive Breast Cancer Accepted by FDA
A new drug application (NDA) for neratinib as an extended adjuvant therapy for patients with HER2-positive breast cancer following prior treatment with postoperative trastuzumab (Herceptin) has been accepted by the FDA
FDA Gives Niraparib Fast Track Designation for Ovarian Cancer
Niraparib has been granted a fast track designation by the FDA as a treatment for women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer